SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

PRX019

PRTA·PROTHENA CORP PUBLIC LTD CO
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 1 (completed)
Time to market
Not applicable. BMS terminated the license after Phase 1; the drug is no longer in active development.
Why 3/10
The next hard catalyst for PRX019 was BMS's decision on whether to advance it, which occurred on October 28, 2026 (negative outcome). No further binary catalysts exist for this drug; the license termination effective date of January 28, 2027 is administrative. ImpactScore is low because the defining binary event has already passed and the drug has no future catalysts.
Actionable Insight BEARISH

PRX019 is effectively dead for Prothena after BMS's termination decision on October 28, 2026. The license agreement formally ends January 28, 2027, but no further payments are owed. All attention now shifts to the moponetug (PRX005) Alzheimer's program, where BMS is running the Phase 2 TargetTau-1 trial with data expected in H1 2027. That readout is Prothena's next major binary catalyst.

Price Chart

Loading chart...

Executive Summary

PRX019 is an investigational monoclonal antibody for neurodegenerative diseases (likely targeting tau protein) that Prothena (PRTA) developed and licensed to Bristol Myers Squibb in May 2024 for $80 million upfront and up to $617.5 million in milestones. A Phase 1 trial in 50 healthy volunteers completed in H1 2026 with benign safety and no immunogenicity. On October 28, 2026, BMS notified Prothena it would not advance PRX019 further after an internal strategic review, terminating the license effective January 28, 2027. Prothena keeps the $80M upfront but loses all future milestone and royalty payments. The stock fell ~2.4% on the news and trades near $8.76, close to its 52-week low.

How It Works

PRX019 is a monoclonal antibody (an engineered protein designed to bind to a specific target in the body) intended to treat neurodegenerative diseases such as Alzheimer's. Its exact molecular target was never publicly disclosed by Prothena or BMS, but Prothena's expertise is in protein dysregulation, and BMS's partnered pipeline includes anti-tau antibodies for Alzheimer's.

Trial Status

A Phase 1 first-in-human, randomized, double-blind, placebo-controlled trial (NCT06699680) enrolled 50 healthy adults in the United States. It completed in H1 2026, demonstrating benign safety and tolerability, no immunogenicity, and dose-dependent pharmacokinetics/pharmacodynamics meeting prespecified targets. BMS decided not to advance the drug further after reviewing the data.

The Two-Sided Case

▲ Bull Case4
Prothena retains the $80 million upfront payment BMS paid in May 2024, which provides a cash buffer.
The Phase 1 trial showed benign safety, no immunogenicity, and dose-dependent PK/PD meeting prespecified targets, suggesting the molecule itself was not problematic.
Top 10% holder William Scully has been aggressively buying PRTA shares throughout September and October 2026, investing over $8 million at prices near current levels.
Analyst consensus remains bullish with 8 buy/strong buy ratings and a mean price target of $21.40, implying significant upside from the ~$8.76 post-termination price.
▼ Bear Case4
BMS terminated the license after Phase 1, meaning the data (while benign) did not justify further investment, casting doubt on the drug's therapeutic potential.
Prothena forfeits up to $617.5 million in potential milestones and tiered royalties that were a key part of the pipeline's future value.
The termination increases Prothena's dependence on the single moponetug (PRX005) Alzheimer's program, which is still in Phase 2 and carries its own clinical and regulatory risk.
The stock already trades near its 52-week low ($7.73) and the termination removes a significant upside driver.

Upcoming Catalysts

  • License termination effective date: January 28, 2027 (administrative, no financial impact)
  • No further clinical development planned for PRX019

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PROTHENA CORP PUBLIC LTD CO 8-K PRTA ·Originating report

Sources · 7

Hover a chip for the title
1 sec.gov2 fiercebiotech.com3 biospace.com4 ir.prothena.com5 clinicaltrials.gov6 tipranks.com7 stocktitan.net